The purpose of this study is to evaluate the effectiveness and safety of JAQBO® Tab. 20 mg(Zastaprazan citrate) patients who have been prescribed the investigational drug.

Multi-center prospective observational study

Inclusion Criteria:

• subjects aged 19 years or older who have been diagnosed with erosive reflux disease (ERD)
• subjects who have voluntarily decided to participate in this observational study and have provided written informed consent after receiving the study information and consent form

Exclusion Criteria:

• Subjects who fall under the contraindications listed in the precautions for use section of the approved labeling for Fexuclu tablets:

  1. Subjects with hypersensitivity or a history of hypersensitivity to the investigational drug or any of its components
  2. Subjects currently taking medications containing atazanavir, nelfinavir, or rilpivirine
  3. Pregnant women, women who may be pregnant, or breastfeeding women
  4. Subjects with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

• Subjects deemed inappropriate for participation in the study at the investigator's discretion.

hospital